2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - 278-282
Treatment Considerations, Supportive Care, Biological Therapies, Transplantation, (CAR)-T Cell Therapies, Biological Processes, CHIP, Hematopoiesis, Immune Mechanism, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, T Cell Lymphoma, Research, AML, Clinical Research, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Pediatric
PAPER

447 Outcomes of hematopoietic cell transplantation in subcutaneous panniculitis-like T-cell lymphoma: A CIBMTR analysis

Daniel Klein Reef, MD, FACP, Kwang Wooahn, PhD2, Tiening Chen, MS3, Jinalben Patel, MPH, BDS4, Cameron J. Turtle, MBBS, PhD5, Peter Riedell, MD6, Craig Sauter, MD7, Alex Francisco Herrera, MD8, Mazyar Shadman, MD, MPH9, Mehdi Hamadani, MD10, Anthony Stack, DO11
1 NYU Perlmutter Cancer Center-Sunset Park, Brooklyn, New York, United States
2 CIBMTR, Milwaukee, Wisconsin, United States
3 CIBMTR, Milwaukee, Wisconsin, United States
4 CIBMTR, Milwaukee, Wisconsin, United States
5 The University of Sydney, Sydney, Australia
6 The University of Chicago, Chicago, Illinois, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 City of Hope Comprehensive Cancer Center, Duarte, California, United States
9 Fred Hutchinson Cancer Center, Seattle, Washington, United States
10 CIBMTR, Milwaukee, Wisconsin, United States, Medical College of Wisconsin, Milwaukee, Wisconsin, United States
11 Fox Chase Cancer Center-Temple University Health System, Philadelphia, Pennsylvania, United States

Introduction:

Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare lymphoma of αβ T-cells involving subcutaneous adipose tissue that accounts for less than 1% of T-cell lymphomas. Although frequently indolent, a subset may have an aggressive course. Hematopoietic cell transplantation (HCT) has been used for high-risk, relapsed or refractory cases; however, evidence supporting autologous (auto) and allogeneic (allo) HCT for SPTCL is limited to case reports and small series. Here, we detail outcomes of the largest cohort of SPTCL patients undergoing HCT reported to date.

Methods:

Patients with SPTCL undergoing first allo or auto HCT from 2008 to June 2024 and reported to the CIBMTR were included. Overall survival (OS), progression-free survival (PFS), and GVHD-free/relapse-free survival (GRFS) were estimated via the Kaplan-Meier estimator. Cumulative incidence of relapse/progression, non-relapse mortality (NRM), GVHD, and hematopoietic recovery were estimated while accounting for competing events. Prognostic associations were assessed by univariable Cox regression within each graft type. Analyses are descriptive without correcting for multiplicity and without comparisons between allo and auto cohorts.

Results:

A total of 129 patients (72 allo, 57 auto) from 69 centers were included. Median age was 35 years in both cohorts (range 11-65 allo, 2-71 auto). In the allo and auto cohorts respectively, 56% and 67% were female, 36.1% and 36.8% were White, 8.3% and 15.8% were Black, 15.3% and 17.5% were Asian, and 6.9% and 10.5% were of Hispanic ethnicity. Karnofsky performance status (KPS) ≥90 was present in 57% and 75% and HCT-comorbidity index (HCT-CI) ≥3 in 31% and 25% (allo/auto). At the time of HCT, 56%/53% were in complete remission (CR), 26%/39% were in partial remission (PR), and 17%/4% were chemoresistant or untreated. Median time from diagnosis to HCT was 12.7/11.4 months. Among allo recipients, 46% received myeloablative conditioning; donors were matched-related (MRD) in 46%, matched-unrelated (MUD) in 25%, haploidentical in 15%, and mismatched-unrelated (MMUD) in 14%; post-transplant cyclophosphamide was used in 21%. In the auto cohort, BEAM was the most common conditioning (44%). Median follow-up was 55 months (allo) and 72 months (auto).

Hematopoietic recovery was prompt in both groups, with day +28 neutrophil recovery in 95.8% (allo) and 96.5% (auto), and day +100 platelet recovery in 98.2% and 100%. 5-year OS was 87.3% (allo; 95% CI 78.5-94.0) and 82.4% (auto; 70.6-91.7). 5-year PFS was 82.3% (allo; 72.2-90.4) and 65.3% (auto; 50.9-78.4). 5-year cumulative incidence of relapse was 10.5% (allo; 4.2-19.1) and 26.3% (auto; 14.6-40.0), and 5-year NRM was 7.2% (allo; 2.3-14.5) and 8.4% (auto; 2.1-18.4). 5-year GRFS (allo) was 55.2% (5-year 95% CI 43.2-66.9). Acute grade II-IV and III-IV GVHD at 6 months were 25.3% and 8.6%, and 3-year all-grade and moderate/severe chronic GVHD were 42.8% and 24.5%, respectively.

By univariable analysis, chemoresistant/untreated disease (vs. CR) predicted worse OS (HR 9.96, 95% CI 2.87-42.7; p<0.001) and PFS (HR 10.4, 3.10-34.7; p<0.001) after allo HCT; age ≥40 years was also associated with worse allo OS (HR 3.75, 1.08-13.0; p=0.038). Donor type, time to HCT, conditioning intensity, transplant era, and GVHD prophylaxis were not significantly associated with OS or PFS. After auto HCT, PR (vs. CR) (HR 2.99, 1.17-8.35; p=0.022) and KPS <90 (HR 2.76, 1.01-7.52; p=0.048) at the time of auto HCT were associated with worse PFS. No covariate was significantly associated with OS after auto HCT.

Conclusions:

In the largest reported series of HCT for SPTCL to date, both allo and auto HCT produced durable disease control, with 5-year OS exceeding 80%, low NRM (<10%), and prompt engraftment. Although we do not directly compare the allo and auto cohorts, we note that the numerically higher 5-year PFS after allo vs. auto (82.3% vs. 65.3%) corresponds to a lower 5-year incidence of relapse (10.5% vs. 26.3%). Across both cohorts, disease status at HCT was the most consistent prognostic factor. Although conclusions are limited by retrospective design and relatively small sample size, these data indicate that allo and auto HCT are viable treatment options in SPTCL and provide a benchmark for future prospective studies.
Daniel Klein Reef, MD, FACP: Summit Therapeutics - Current equity holder in publicly-traded company; Summit Therapeutics - Stock (publicly traded); Beam Therapeutics - Stock (publicly traded); Intellia Therapeutics - Stock (publicly traded); Intellia Therapeutics - Divested equity in a private or publicly-traded company in the past 24 months; Regeneron Pharmaceuticals - Divested equity in a private or publicly-traded company in the past 24 months; Beam Therapeutics - Divested equity in a private or publicly-traded company in the past 24 months